SCOTTSDALE, AZ, — Chimeric antigen receptor T-cell therapy had “unprecedented” and “astonishing” results in lupus, but whether it will truly revolutionize rheumatology care remains to be seen, according to a speaker.
“Everybody is jumping on the CAR-T cell bandwagon,” William Rigby, MD, vice chair of the department of medicine and professor of medicine and microbiology at the Geisel School of Medicine at Dartmouth in Lebanon, New Hampshire, told attendees at the Basic and Clinical Immunology for the Busy Clinician symposium. “It may be the